Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study

Uri Kopylov(Sheba Medical Center), Marc Ferrante(Universitair Ziekenhuis Leuven), Nikolaos Kamperidis(St Mark's Hospital), Xavier Roblin(Centre Hospitalier Universitaire de Saint-Étienne), Gionata Fiorino(Carlo Forlanini Hospital), Ariella Bar‐Gil Shitrit, Taina Sipponen(University of Helsinki), Dimitrios Christodoulou(University of Ioannina), Naila Arebi, Peter Bossuyt(Imelda Hospital), Irit Avni‐Biron, Gerassimos J. Mantzaris(European CanCer Organisation), Christian Maaser(Klinikum Lüneburg), Iris Dotan(Tel Aviv University), Britta Siegmund(Humboldt-Universität zu Berlin), Torsten Kucharzik(Klinikum Lüneburg), Luc Biedermann(University of Zurich), Bram Verstockt(Universitair Ziekenhuis Leuven), Daniel C. Baumgart(University of Alberta), Laurent Peyrin‐Biroulet(Délégation Centre-Est), P Steinhagen(Humboldt-Universität zu Berlin), Shaji Sebastian(University of Hull), Emmanouela Tsoukali(KU Leuven), Alessandro Armuzzi, Tim Raine(National Health Service), Shomron Ben‐Horin(Tel Aviv University), Bella Ungar(Sheba Medical Center), Henit Yanai(Tel Aviv University), Sandro Ardizzone(European CanCer Organisation), Marina Coletta(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniela Pugliese(Agostino Gemelli University Polyclinic), Mariangela Allocca(Vita-Salute San Raffaele University), Nitsan Maharshak(Yale University), Elena Sonnenberg(Charité - Universitätsmedizin Berlin), Κωνσταντίνος Κατσάνος(University of Ioannina), Yulia Ron(Tel Aviv University), Rami Eliakim(Sheba Medical Center), Pauliina Molander(University of Helsinki)
Inflammatory Bowel Diseases
May 18, 2018
Cited by 70


Related Papers